#1 Clinical Trials Search in Europe

Tacrolimus Monohydrate

This article discusses a clinical trial investigating the use of Tacrolimus Monohydrate, specifically the Adoport® formulation, in patients who have recently undergone kidney transplantation. The study aims to understand the drug’s pharmacokinetics and develop better methods for monitoring its levels in patients’ blood, which is crucial for preventing organ rejection and minimizing side effects.

Table of Contents

What is Tacrolimus Monohydrate (Adoport®)?

Tacrolimus Monohydrate, marketed under the brand name Adoport®, is a medication widely used in transplant medicine[1]. It belongs to a class of drugs called calcineurin inhibitors, which are crucial in preventing organ rejection after transplantation. Adoport® is specifically designed as an immediate-release formulation of tacrolimus, meaning it quickly releases the medication into your body. This formulation is typically taken twice daily to maintain consistent levels of the drug in your system.

How Does Tacrolimus Work?

Tacrolimus works by suppressing your immune system to prevent it from attacking and rejecting the transplanted kidney[1]. By inhibiting an enzyme called calcineurin, tacrolimus reduces the activity of certain immune cells that would otherwise recognize the new kidney as foreign and attempt to destroy it. This immunosuppressive action is vital for the success of your kidney transplant, allowing your body to accept the new organ.

Therapeutic Drug Monitoring

One of the critical aspects of using Adoport® is the need for careful monitoring of drug levels in your blood. This process is called Therapeutic Drug Monitoring (TDM)[1]. TDM is essential because tacrolimus has what doctors call a “narrow therapeutic index.” This means that the difference between an effective dose and a potentially harmful dose is small. Regular monitoring helps ensure that you’re receiving the right amount of medication to prevent rejection while minimizing side effects.

Doctors typically measure the trough concentration of tacrolimus in your blood. This is the lowest level of the drug in your system, usually just before you’re due to take your next dose. However, some experts believe that measuring the area under the curve (AUC), which represents your total exposure to the drug over time, might be even more accurate[1].

Genetic Factors Affecting Tacrolimus

Interestingly, your body’s response to tacrolimus can be influenced by your genetic makeup. Specifically, a variation in a gene called CYP3A5 can affect how quickly your body processes the drug[1]. People who have at least one copy of a specific version of this gene (called CYP3A5*1) may need higher doses of tacrolimus to achieve the same effect as those who don’t have this gene variant. This genetic factor is one reason why personalized dosing and careful monitoring are so important when using Adoport®.

Current Clinical Study on Adoport®

A clinical trial is currently underway to study the pharmacokinetics (how the body processes the drug) of Adoport® in patients who have recently received a kidney transplant[1]. The study aims to:

  • Develop a method to accurately predict tacrolimus levels in the blood using fewer blood samples. This could make monitoring more convenient for patients in the future.
  • Evaluate how well their prediction model works, especially considering genetic factors like the CYP3A5 gene variation.
  • Improve understanding of how Adoport® behaves in the body, which could lead to more personalized and effective dosing strategies.

Importance of Tacrolimus in Transplantation

Tacrolimus, including the Adoport® formulation, plays a crucial role in kidney transplantation[1]. It helps to:

  1. Prevent acute rejection: By suppressing the immune response, tacrolimus significantly reduces the risk of your body rejecting the new kidney in the critical period following transplantation.
  2. Improve long-term outcomes: Proper use of tacrolimus can contribute to better long-term survival of the transplanted kidney.
  3. Balance benefits and risks: While tacrolimus is very effective, it can have side effects. The most common are kidney toxicity and, less frequently, nervous system effects. This is why careful monitoring and dosing are so important.

In conclusion, Adoport® (tacrolimus monohydrate) is a vital medication for kidney transplant recipients. While it requires careful management and monitoring, it plays a crucial role in helping your body accept and maintain your new kidney. Always follow your doctor’s instructions closely and attend all scheduled follow-up appointments to ensure the best possible outcomes from your transplant and tacrolimus therapy.

Aspect Details
Drug Name Tacrolimus Monohydrate (Adoport®)
Purpose Prevention of allograft rejection in kidney transplant patients
Administration Twice daily, immediate-release formulation
Key Challenge Narrow therapeutic index and large inter-individual pharmacokinetic variability
Primary Outcome Evaluation of Bayesian estimator performance in predicting Tacrolimus AUC
Secondary Outcome Prediction of Tacrolimus concentrations using limited sample strategy
Genetic Consideration CYP3A5 polymorphism’s impact on Tacrolimus pharmacokinetics

FAQ

  • What is Tacrolimus Monohydrate used for in this clinical trial? Tacrolimus Monohydrate, specifically the Adoport® formulation, is used to prevent organ rejection in patients who have recently received a kidney transplant.
  • Why is monitoring Tacrolimus levels important? Monitoring Tacrolimus levels is crucial because the drug has a narrow therapeutic index, meaning the effective dose is close to the toxic dose. Proper monitoring helps minimize the risk of acute rejection and reduce the occurrence of side effects like kidney and nerve damage.
  • What is the main goal of this clinical trial? The main goal is to develop and evaluate a Bayesian estimator that can accurately predict Tacrolimus levels in the blood using a limited number of blood samples, making it easier to monitor drug levels in routine clinical practice.
  • How does genetics play a role in this study? The study considers a genetic factor called CYP3A5, which affects how patients metabolize Tacrolimus. Patients with a specific genetic variant may require higher doses of the drug to achieve the same effect.
  • How often is Adoport® administered to patients in this trial? Adoport® is an immediate-release formulation of Tacrolimus that is administered twice daily to patients in this trial.

Ongoing Clinical Trials on Tacrolimus Monohydrate

  • Study on How Tacrolimus Monohydrate and Mycophenolate Mofetil Affect Gut Bacteria in Patients with Chronic Kidney Disease After Transplant

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • A Study Comparing Tacrolimus and Ciclosporin Eye Drops for Children and Adults with Moderate to Severe Vernal Keratoconjunctivitis

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Bulgaria France Greece Italy Spain

  • Study on Optimizing Immunosuppressive Treatment for Living Donor Kidney Transplant Patients Using Prednisone, Basiliximab, and Tacrolimus Monohydrate

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study on Skin Care for Patients with Advanced EGFR-Mutated Lung Cancer Treated with Amivantamab and Lazertinib

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain

Glossary

  • Tacrolimus: A medication used to prevent organ rejection in transplant patients by suppressing the immune system.
  • Calcineurin inhibitor: A class of drugs, including Tacrolimus, that work by blocking the action of calcineurin, an enzyme important in immune system activation.
  • Therapeutic index: The range between the amount of a drug that causes a therapeutic effect and the amount that causes toxicity.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Therapeutic Drug Monitoring (TDM): The practice of measuring specific drug levels in the blood to optimize individual dosages.
  • Area Under the Curve (AUC): A measurement of drug exposure over time, used to assess the total amount of drug in the body.
  • Bayesian estimation: A statistical method used to estimate drug levels based on limited blood samples and known population data.
  • CYP3A5: An enzyme involved in drug metabolism, which can affect how quickly Tacrolimus is processed in the body.
  • Polymorphism: A variation in DNA sequence among individuals, groups, or populations.
  • de novo: A Latin phrase meaning 'from the beginning,' used here to refer to newly transplanted kidneys.

References

  1. https://clinicaltrials.gov/study/NCT03076151